Stefan C. Grant

2.5k total citations
45 papers, 1.4k citations indexed

About

Stefan C. Grant is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Stefan C. Grant has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Stefan C. Grant's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (13 papers) and Cancer therapeutics and mechanisms (6 papers). Stefan C. Grant is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (13 papers) and Cancer therapeutics and mechanisms (6 papers). Stefan C. Grant collaborates with scholars based in United States, Egypt and United Kingdom. Stefan C. Grant's co-authors include Mark G. Kris, Vincent A. Miller, Paul B. Chapman, Alan N. Houghton, James R. Rigas, Katherine M.W. Pisters, Kenneth Ng, Prudence A. Francis, W. Jeffrey Petty and Jimmy Ruiz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Stefan C. Grant

44 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan C. Grant United States 22 786 524 372 292 176 45 1.4k
Yoichiro Kakugawa Japan 21 625 0.8× 483 0.9× 309 0.8× 163 0.6× 176 1.0× 52 1.4k
Toshimitsu Yamaoka Japan 21 645 0.8× 529 1.0× 525 1.4× 185 0.6× 178 1.0× 51 1.4k
Mireille Mousseau France 16 663 0.8× 651 1.2× 635 1.7× 174 0.6× 322 1.8× 40 1.5k
Jürgen R. Fischer Germany 25 972 1.2× 704 1.3× 632 1.7× 498 1.7× 303 1.7× 70 1.9k
Sebastian Hinz Germany 17 568 0.7× 408 0.8× 189 0.5× 366 1.3× 268 1.5× 41 1.3k
Zhengtang Chen China 24 813 1.0× 835 1.6× 196 0.5× 345 1.2× 396 2.3× 49 1.6k
Stephen Welch Canada 24 1.0k 1.3× 626 1.2× 388 1.0× 96 0.3× 279 1.6× 124 1.9k
Tomoyuki Nagai Japan 24 528 0.7× 599 1.1× 409 1.1× 147 0.5× 260 1.5× 95 1.7k
Stephen M. Schleicher United States 19 373 0.5× 609 1.2× 230 0.6× 194 0.7× 171 1.0× 62 1.3k
Oscar Alabiso Italy 24 651 0.8× 427 0.8× 450 1.2× 94 0.3× 280 1.6× 60 1.5k

Countries citing papers authored by Stefan C. Grant

Since Specialization
Citations

This map shows the geographic impact of Stefan C. Grant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan C. Grant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan C. Grant more than expected).

Fields of papers citing papers by Stefan C. Grant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan C. Grant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan C. Grant. The network helps show where Stefan C. Grant may publish in the future.

Co-authorship network of co-authors of Stefan C. Grant

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan C. Grant. A scholar is included among the top collaborators of Stefan C. Grant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan C. Grant. Stefan C. Grant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lycan, Thomas, et al.. (2021). P48.01 Gemcitabine and Nivolumab for Subsequent Treatment of Metastatic Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S499–S499. 3 indexed citations
2.
Lee, Carrie B., Theresa L. Werner, Allison M. Deal, et al.. (2020). Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers. JCO Oncology Practice. 17(1). e77–e93. 8 indexed citations
3.
Ahmed, Tamjeed, Thomas Lycan, Jimmy Ruiz, et al.. (2020). Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 21(4). e286–e293. 27 indexed citations
4.
McLouth, Laurie E., Thomas Lycan, Beverly J. Levine, et al.. (2019). Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice. Clinical Lung Cancer. 21(3). 255–263.e4. 34 indexed citations
5.
Hong, David S., Kathleen N. Moore, Manish R. Patel, et al.. (2018). Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clinical Cancer Research. 24(14). 3263–3272. 62 indexed citations
6.
Arafat, Waleed, et al.. (2018). A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer. Journal of Cancer Therapy. 9(3). 314–322. 1 indexed citations
7.
Arafat, Waleed, et al.. (2017). P2.03a-033 Prediction of Response to First Line Treatment for Metastatic Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S908–S908. 1 indexed citations
8.
Yang, Mei, M. Elizabeth Forbes, Rhonda L. Bitting, et al.. (2017). Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?. Annals of Oncology. 29(2). 311–323. 72 indexed citations
9.
Allendorf, Daniel J., Rodolfo Bordoni, Stefan C. Grant, et al.. (2015). Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC). Cancer Chemotherapy and Pharmacology. 76(5). 949–955. 1 indexed citations
10.
Sawant, Anandi, Tong Huan Jin, Jaroslaw W. Zmijewski, et al.. (2013). Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways. Cancer Research. 73(22). 6609–6620. 70 indexed citations
11.
Rigas, James R., Mark G. Kris, V.A. Miller, et al.. (1999). Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Annals of Oncology. 10(5). 601–603. 8 indexed citations
12.
Pisters, Katherine M.W., et al.. (1999). Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Supportive Care in Cancer. 7(1). 44–46. 5 indexed citations
13.
Kindler, Hedy L., Mark G. Kris, Ian E. Smith, et al.. (1998). Phase II Trial of Topotecan Administered as a 21-Day Continuous Infusion in Previously Untreated Patients With Stage IIIB and IV Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 21(5). 438–441. 21 indexed citations
14.
Miller, V. A., Kenneth Ng, Stefan C. Grant, et al.. (1997). Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology. 8(12). 1269–1271. 48 indexed citations
15.
Miller, Vincent A., James R. Rigas, William P. Tong, et al.. (1997). Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 40(5). 415–418. 14 indexed citations
16.
Grant, Stefan C., Lale Kostakoğlu, Mark G. Kris, et al.. (1996). Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial. European Journal of Nuclear Medicine and Molecular Imaging. 23(2). 145–149. 43 indexed citations
17.
Miller, Vincent A., James R. Rigas, Prudence A. Francis, et al.. (1995). Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75(4). 968–972. 104 indexed citations
18.
Francis, Prudence A., Mark G. Kris, James R. Rigas, Stefan C. Grant, & Vincent A. Miller. (1995). Paclitaxel (Taxol) and Docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer. 12. S163–S172. 38 indexed citations
19.
Miller, Vincent A., James R. Rigas, Stefan C. Grant, Katherine M.W. Pisters, & Mark G. Kris. (1995). New Chemotherapeutic Agents for Non-small Cell Lung Cancer. CHEST Journal. 107(6). 306S–311S. 37 indexed citations
20.
Grant, Stefan C., Mark G. Kris, Richard J. Gralla, Rebecca A. Clark, & Leslie B. Tyson. (1993). Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy. Cancer Chemotherapy and Pharmacology. 31(6). 442–444. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoichiro Kakugawa Breakdown of academic impact, for papers by Toshimitsu Yamaoka Breakdown of academic impact, for papers by Mireille Mousseau Breakdown of academic impact, for papers by Jürgen R. Fischer Breakdown of academic impact, for papers by Sebastian Hinz Breakdown of academic impact, for papers by Zhengtang Chen Breakdown of academic impact, for papers by Stephen Welch Breakdown of academic impact, for papers by Tomoyuki Nagai Breakdown of academic impact, for papers by Stephen M. Schleicher Breakdown of academic impact, for papers by Oscar Alabiso
Rankless by CCL
2026